Onychomycosis (Tinea Unguium) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Onychomycosis (Tinea Unguium) – Drugs In Development, 2024 report and make more profitable business decisions.
Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail, and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.
The Onychomycosis (Tinea Unguium) drugs in development market research report provide comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Onychomycosis (Tinea Unguium) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Onychomycosis (Tinea Unguium) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Onychomycosis (Tinea Unguium) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Onychomycosis (Tinea Unguium) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Almirall SAAmtixbio Co Ltd
ASCIL Biopharm
Blueberry Therapeutics Ltd
China Medical System Holdings Ltd
CSA Biotechnologies LLC
Hallux Inc
Moberg Pharma AB
Mycovia Pharmaceuticals Inc
NAL Pharmaceuticals Ltd
Nektr Technologies Ltd
Photonamic GmbH & Co KG
SaNOtize Research and Development Corp
Tianjin Institute of Pharmaceutical Research
TIPR-HUYA Advancing Innovative Medicines
TTY Biopharm Co Ltd
Turn Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Onychomycosis (Tinea Unguium) reports